Table 4.
Estimated potential number of patients eligible for carbon ion radiotherapy in the United States in 2025.
|
Disease site |
Estimated patients eligible for CIRT in 2019, No. |
Estimated percentage of growth [by Pan et al ], % |
Estimated patients eligible for CIRT in 2025, No. |
US estimation for 2025, No. |
| Glioblastoma | 5205 | 13 | 5881 | 1176 |
| Head and neck | 4154 | 18 | 4901 | 490 |
| Hepatocellular carcinoma | 31 120 | 22 | 37 967 | 4556 |
| Cholangiocarcinoma | 4036 | 18 | 4763 | 572 |
| Pancreas | 28 695 | 23 | 35 295 | 706 |
| Non–small cell lung cancer | 129 816 | 24 | 160 972 | 22 536 |
| Prostate | 143 836 | 30 | 186 986 | 80 404 |
| Soft tissue sarcomas | 12 381 | 18 | 14 610 | 4383 |
Abbreviation: CIRT, carbon-ion radiotherapy.